Oncolytics Biotech expects final GOBLET Cohort 4 results in Q4 2026
ONCY•Oncolytics Biotech expects final GOBLET Cohort 4 results in Q4 2026 and initial Cohort 5 results in the first half of 2027. The company said every fully enrolled cohort met its prespecified efficacy success criteria; Cohort 4 survival exceeded expectations, while Cohort 5 outcomes continue to mature.
1. Study results timeline
Cohort 4 tests pelareorep with atezolizumab in anal cancer, while Cohort 5 evaluates pelareorep-based combinations in previously untreated metastatic pancreatic cancer. Cohort 5 reporting could be delayed as patients remain under treatment or follow-up, and its findings will guide pelareorep’s development with checkpoint inhibitors.
2. Grant and follow-up
The final PanCAN grant payment is expected this quarter, with enrollment complete. Broader study infrastructure is winding down while patient follow-up continues.
